Trinity Biotech (Trinity Biotech) Debt-to-Equity

: -3.83 (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

Trinity Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.81 Mil. Trinity Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $65.21 Mil. Trinity Biotech's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-17.49 Mil. Trinity Biotech's debt to equity for the quarter that ended in Sep. 2023 was -3.83.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Trinity Biotech's Debt-to-Equity or its related term are showing as below:

TRIB' s Debt-to-Equity Range Over the Past 10 Years
Min: -661.77 Med: 0.87 Max: 107.01
Current: -3.83

During the past 13 years, the highest Debt-to-Equity Ratio of Trinity Biotech was 107.01. The lowest was -661.77. And the median was 0.87.

TRIB's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.24 vs TRIB: -3.83

Trinity Biotech Debt-to-Equity Historical Data

The historical data trend for Trinity Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

1.87

21.68

-47.02

-310.84

-33.18

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity																8.73	-33.18	-11.63	-5.92	-3.83

Competitive Comparison

For the Diagnostics & Research subindustry, Trinity Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trinity Biotech Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Debt-to-Equity falls into.

Trinity Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Trinity Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.886	+	70.314)	/	-2.176
	=	-33.18

Trinity Biotech's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.81	+	65.205)	/	-17.487
	=	-3.83

Trinity Biotech (NAS:TRIB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Trinity Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.